Skip to content
Pharma Observatory a Scientist.com platform
  • Supplier site
  • Group of sites (click to zoom)

Scientist.com supplier network (site locations)

Research supplier

Afraxis

Afraxis is listed as a small business research supplier in the Scientist.com network, with 3 sites in 1 country and 1 service area.

View Afraxis on Scientist.com

Sign in to Scientist.com to open this supplier in your organization's marketplace.

Email me this page as a PDF

Search companies, drugs, suppliers and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Sites 3
Countries 1

Services

What this research supplier says it provides, as listed in the Scientist.com network.

Type of company: Small business

Disease Models

  • Excitotoxicity Models Measure therapeutic endpoints in animal models with excitotoxic pathology.
  • Huntington's Disease Models Measure therapeutic endpoints in animal models of Huntington's disease.
  • Neuroscience Models Test therapeutic efficacy of drug candidate in neurological disease model.
  • Schizophrenia Models Measure therapeutic endpoints in animal models of schizophrenia.
  • Stroke Models Measure therapeutic endpoints in animal models of stroke.

In Vitro Pharmacology

  • In Vitro Excitotoxicity Models Use in vitro models to measure therapeutic endpoints associated with excitotoxic pathology.
  • In Vitro Neural Models Use cultured neurons, neuronal progenitor cells and stem cell differentiation to create cellular models of neurological disease.

Service areas:

Biology

Source: Scientist.com supplier network

Where it operates

Sites by country, with the cities in each.

  • United States San Diego 3 sites

Source: Scientist.com supplier network (site locations)

About this supplier

In the supplier's own words, as listed in the Scientist.com network.

Afraxis Inc. develops high-content CNS pharmaceutical screening technologies to evaluate pre-clinical therapeutics for the treatment of neurological and psychiatric disorders. Afraxis developed the emergent technology Afraxis ESP (Enhanced Spine Analysis Platform), which quantifies the morphology and maturity of synaptic dendritic spines which are fundamental to information processing by neural synapses in the brain. Afraxis is part of a growing wave of innovative Neuroscience that applies cutting-edge technical and computational approaches to fundamental issues in brain science that...

Show the full description

Afraxis Inc. develops high-content CNS pharmaceutical screening technologies to evaluate pre-clinical therapeutics for the treatment of neurological and psychiatric disorders. Afraxis developed the emergent technology Afraxis ESP (Enhanced Spine Analysis Platform), which quantifies the morphology and maturity of synaptic dendritic spines which are fundamental to information processing by neural synapses in the brain. Afraxis is part of a growing wave of innovative Neuroscience that applies cutting-edge technical and computational approaches to fundamental issues in brain science that promise to generate new insights into CNS diseases.

Afraxis Inc. is a San Diego-based spin-out company co-founded by Afraxis Holdings, Christopher Rex and Carmine Stengone in April 2013.

Website
www.afraxis.com

Source: Scientist.com supplier network, written by the supplier

Get the Afraxis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Sources: Scientist.com supplier network.

Work with Afraxis on Scientist.com

For prices, more details, or to contact Afraxis, visit Scientist.com.

View on Scientist.com

Sign in to Scientist.com to open this supplier in your organization's marketplace.